Member Info for Spikeyj

"I don't think that MMs can cherry pick, but by controlling their individual bid/offer prices and looking at the order book they can fine tune when they trade stock and at what price. " yes, & they can also choose to take a back seat sometimes by making their bid/offer prices not just a little bit wide, but also by making them only good for only fairly limited size too. (although from a reputation/machismo perspective, the bigger market-makers doesn't want to be seen going that too often.)

under the cosh bought a few

glacially paced, but in the right direction (for now).

seems reasonably robust in relative terms. atb.

... for a percentage ...

i think that came out a while ago. (according to HL, goldman uprated vod to conviction buy back on 8/3, reiterating 24/3.)

hi char, thanks for your reply. i confess, i don't really understand why you are still holding onto vodafone, given that you state: "Still think this will stick between £2 + £2 10." ... there's an awful lot of different shares out there, literally thousands of them; surely a few of them must offer u better prospects than just Vod dividend & £2.10? i know i would not stay in a share myself where i expected the return to be so low. but your choice, of course. gl & atb.

nice one!

char33: "I go back to my prediction in late December 2016 that this wont reach £ 2 20 by end of this year." char, if you don't mind me asking, why are you still holding VOD? if you think the max upside here by end 2017 is only 10 or 11 pence away, it's hard to see why that possibility + the dividend here would outweigh some other shares out there. (no offence meant, but curious.) can you see other shares out there in the market which you feel have better upside prospects?

are enthusiastic, £6 target. which would be nice, if only these darn broker ratings ever meant anything (sigh).

& another tad.

https://www.pressreader.com/kuwait/kuwait-times/20170325/282299614996893/textview

ADVAIR CHALLENGE FOR GSK The picture is a lot less certain for Britain's GSK as it faces the threat of cut-price competition from Mylan, which hopes to secure approval for the first substitutable generic copy of GSK's top-selling Advair lung drug by March 28. Mylan believes it has done everything required to win FDA approval but its version of Advair would be the first complex inhaled combination generic product to be approved by the U.S. agency, so nothing is guaranteed. That complexity has led some analysts to question whether Mylan will succeed at its first attempt to gain approval, potentially delaying the arrival of generics and shielding GSK's profits from immediate attack. A second generic version of Advair from Hikma Pharmaceuticals and Vectura is also awaiting an FDA approval decision by May 10. Dealing with the threat of competition to Advair, which has generated more than $1 billion in annual sales since 2001, is the first big challenge facing GSK's new chief executive, Emma Walmsley, who takes over at the end of this month. GSK has told the market that core earnings per share, in constant currencies, will be flat to slightly lower in 2017, if substitutable Advair generics arrive in the United States by mid-year. If they don't launch, EPS should rise between 5 and 7 percent. (Editing by Greg Mahlich)

Societe Generale today reaffirms its buy investment rating on AstraZeneca PLC [LON:AZN] and set its price target at 7600p. ... but on the other hand, they are french...

and bought a few back today. (probably too soon, but i don't have that much else in my p/f currently that levers into far east.)

http://www.standard.co.uk/business/vodafone-inks-23bn-deal-in-india-price-war-a3494156.html

RNS worth a glance, just re indian mobile money contexts.

volume was very chunky. perhaps holding RNS due?

meanwhile, http://indianexpress.com/article/technology/tech-news-technology/vodafone-teams-up-with-amazon-prime-video-for-a-special-offer/

clear, accurate, helpful.